On a separate but related note, a pharmacokinetic study of zotiraciclib, conducted as part of a phase I trial for patients with recurrent anaplastic astrocytoma and glioblastoma (NCT02942264) (see Section 5.2), revealed a significant increase in patient plasma concentrations of cytokines, including IP-10, at 24 h after an oral dose of zotiraciclib [69]. This evidence concerns the gene CXCL10 and glioblastoma.